PepGen's low-dose DM1 cohort missed on function; next dose is the test
The 5 mg/kg cohort of PepGen's FREEDOM2 trial showed no improvement in handgrip or walking speed, putting weight on the 10 mg/kg readout due in the second half of 2026.
Executive Summary
- PepGen's next FREEDOM2 cohort readout arrives against a low-dose result that showed molecular activity but not the functional gains the company has used to frame the program's promise.
- The lower-dose cohort completed dosing and reported data, and independent analysis found no improvement on the walking and grip-strength measures most relevant to patients, even as the company described the results in more positive terms.
- The trial's completion date moved back several months, extending the runway to the higher-dose cohort's report without altering the trial's core design or its safety-focused primary endpoint.
- No other clinical-stage program in myotonic dystrophy type 1 shares this asset's mechanism, leaving PepGen without a direct peer against which to benchmark whatever functional signal the higher dose produces.
The pending readout
PepGen remains on track to report results from the 10 mg/kg cohort of the FREEDOM2 trial in the second half of 2026, per its most recent guidance. The trial, registered as NCT06667453 and known as FREEDOM2-DM1, is a randomized, placebo-controlled multiple-ascending-dose study enrolling 24 patients with myotonic dystrophy type 1 across sites in Canada, the United Kingdom, and New Zealand. Its registered primary endpoint is safety and tolerability, measured by the number of participants with adverse events, not a functional or efficacy measure. PepGen+1PepGen Reports Third Quarter 2025 Financial Results and Recent Corporate HighlightsNov 12, 2025A Clinical Study of PGN-EDODM1 in People With Myotonic Dystrophy Type 1NCT06667453
Probability of SuccessBased on the AppliedXL Probability of Success model. For more information about the methodology, read the research here.
What the low dose showed
The 5 mg/kg cohort of FREEDOM2 completed enrollment and dosing by late 2025, and PepGen said in November 2025 that all patients in that cohort had received at least one dose. When results were reported in March 2026, the company characterized the data as promising, but analysts reviewing the same data found no improvement in handgrip strength or 10-meter walk/run time, two of the trial's eight secondary endpoints. The trial had also been subject to a prior FDA partial clinical hold. Splicing correction, the drug's mechanistic readout, is not the same measure as functional strength or mobility, and the gap between the two is the open question the 10 mg/kg cohort now carries. PepGenPepGen Reports Third Quarter 2025 Financial Results and Recent Corporate HighlightsNov 12, 2025
The mechanistic case
PepGen's rationale for PGN-EDODM1 rests on data from its earlier single-dose Phase 1 FREEDOM trial, where the 15 mg/kg cohort produced a mean splicing correction of 53.7% in DM1 patients, with all patients showing improvement and adverse events described as mild or moderate. Chief Executive James McArthur said the company expected that degree of splicing correction to translate into functional improvements in myotonia and muscle weakness over time in FREEDOM2. The 5 mg/kg multi-dose cohort's result did not confirm that translation on the two functional measures analysts examined. PepGenPepGen Reports Third Quarter 2025 Financial Results and Recent Corporate HighlightsNov 12, 2025
Timing and trial mechanics
The trial's primary completion date moved from August 1, 2026 to March 1, 2027, a change recorded in the registry on April 28, 2026. Enrollment held flat at its target of 24 patients, and the trial has logged one primary-completion-date change and two eligibility-criteria edits since it opened, a change pattern the registry classifies as stable. The status has remained Recruiting since December 2024. NCT06667453A Clinical Study of PGN-EDODM1 in People With Myotonic Dystrophy Type 1NCT06667453
The competitive field
Myotonic dystrophy type 1 carries at least eight active industry trials, spanning small molecules, antisense oligonucleotides, RNA therapies, and gene therapy, none of which shares PGN-EDODM1's target. The most advanced programs, including Avidity Biosciences' delpacibart etedesiran and Dyne Therapeutics' zeleciment basivarsen, are both in Phase 3 and target DMPK rather than PepGen's target, so neither offers a mechanism-matched benchmark for FREEDOM2's functional results. With no validated disease-modifying mechanism established in this indication, a functional gain that reproduces or exceeds what the molecular splicing-correction data implied, on measures like grip strength or walking speed, would be the result that distinguishes the higher dose from the lower one.
This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.